• Goldman Sachs’s yearly report on the global music industry expects music streaming revenues to reach $89.3 billion in 2030, with paid streaming contributing $55.6 billion and ad-funded streaming contributing $33.7 billion of the total
• Friendable’s 360-degree artist platform offers independent music artists the tools they need to produce, distribute, and market their music while generating (and keeping) revenue
• On average, artists lose 90% of streaming revenue to record labels, 10% to booking agents, and 15-20% of overall income to managers while feeling unsupported and controlled by these labels

The highly coveted yearly music industry update released by Goldman Sachs strives to answer the billion-dollar question – how much will the music industry be worth in 2030? The update suggests that global music streaming revenues will reach $89.3 billion in 2030, with paid streaming contributing $55.6 billion and ad-funded streaming contributing $33.7 billion. Goldman Sachs analyst Lisa Yang and a team of colleagues penned the company’s report citing that the reduced increase in its projection numbers is driven by higher paid streaming annual revenue per user and ad-funded streaming assumptions. The decrease also includes the decline in physical sales (https://ibn.fm/hbiqv). On average, artists lose 90% of streaming revenue to record labels, 10% to booking agents, and 15-20% of overall income to managers. The fees are not the only problem; most artists feel a lack of support and a lack of control, in addition to their financially burdensome strict financial contracts. In the changing landscape of the music industry, labels must be willing to adapt, and Friendable’s (OTC: FDBL) 360-degree streaming artist platform offers the solution for them to do that. Friendable is a mobile technology and marketing company focused on developing its Fan Pass Live artist platform and related-branded products. The 360-degree streaming artist platform is comprised of Fan Pass Live, Artist Republik, and FeaturedX – providing artists with everything they need to produce, distribute, and market their music without the contractual obligations placed on them by record labels. It provides opportunities for independent artists looking to find their footing in the industry and leverage the increase in the streaming industry. For artists, growth and other vital resources are locked behind walls of contracts and middlemen. There is no easy way to advance their careers without a solution that gives artists access to resources and elevates their careers. Partnering with the Fan Pass Live artist platform can give labels the tools they need to help advance artist careers. Artists have multiple advantages working with Fan Pass Live, Artist Republik, and FeaturedX platforms, including:

• Music distribution and management
• Music production assistance
• Press release and Instagram promotion
• Digital storefront activation
• Artist marketplace for collaborations
• Merchandise, logo, and promotional design support
• Virtual concert booking and ticketing mobile streaming service
• Live streaming support
• Revenue from fan tips, monthly artist contests, merchandise, and ticket sales
• Access to fan data and performance analytics
• Artist contests
• NFT Development and Metaverse performances – coming soon

In the future, Friendable will add NFT development and Metaverse performances to the artist offering. With NFTs changing the way we understand digital ownership and commerce, the company will use non-fungible tokens as a means for creators to generate additional revenue through the sales and distribution of their music. These NFTs will provide artists with an additional offering that can be traded or sold to fans, collectors, and music enthusiasts. Through Friendable’s Fan Pass Live artist platform, independent artists are gaining a distinctive advantage and entry into the streaming industry, not controlled by contracts or labels. The platform is built by artists, for artists. As a one-stop shop, Fan Pass Live and its branded assets provide a singular platform for artists to grow their audience, interact with fans, promote music, showcase work, sell merchandise, and generate revenue. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Medical costs for concussions total $20 billion in the United States, a need for which there is no FDA-approved treatment
• The CDC estimates that more than 50% of people suffering a traumatic brain injury become moderately or severely disabled and have shorter life spans
• Odyssey provides a portfolio of diverse technologies and related medical products to meet the unmet medical needs of concussion and TBI patients

Each year, medical costs in the United States for concussions total $20 billion ($400 billion worldwide). There is a significant unmet medical need for treatments for concussions in the medical landscape, with most diagnosed patients sent home with a standard of care involving rest, analgesics for headaches, and anti-depressants. Repeat concussions can lead to early dementia and Chronic Traumatic Encephalopathy (“CTE”), with the likelihood of athlete head injury recurrence totaling 75% (https://ibn.fm/z6bKU). Currently, there is no FDA-approved drug treatment for concussions, with the CDC noting that about 50% of people with traumatic brain injury (“TBI”) will experience decline in their daily lives or die within five years of their injury, while 57% will become moderately or severely disabled (https://ibn.fm/f5dvW). Odyssey Health (OTC: ODYY), a medical technology company focused on lifesaving medical products that offer technological and clinical advantages over current standards of care, is moving forward in its quest to meet the unmet needs of concussion patients. Recently, the company announced that its investigational agent PRV-002, a fully synthetic, nonnaturally occurring neurosteroid intended to treat concussion, was reported to be safe and well tolerated in a small cohort of volunteers. The company is currently in the process of selecting clinical sites and developing the Investigator’s Brochure for a Phase 2 trial (https://ibn.fm/e0DMX). Odyssey provides a portfolio of diverse technologies, featuring four unique medical products currently in development. The company aims to deliver superior products with enhanced clinical utility and market potential. Beyond concussion treatment, Odyssey plans to develop treatments of related brain injury and neuropsychiatric disorders with other novel neurosteroids within its portfolio. These indications include major depressive disorder, post-traumatic stress disorder (“PTSD”), dementia, generalized anxiety, addiction, amyotrophic lateral sclerosis (ALS – Lou Gehrig’s Disease), and CTE. The company’s advisory boards play a vital role in developing novel treatments for unmet medical needs. The Scientific Advisory Board consists of James P. Kelly, MA, MD, FAAN, the Executive Director of the Marcus Institute for Brain Health (“MIBH”), and Professor of Neurology at the University of Colorado Anschutz Medical Campus. In addition to Dr. Kelly, the board includes Dallas C. Hack, MD, MPH, FACMPH, COL, US Army. Dr. Hack is also a Brain Health Consultant working with the NCAA, DoD, and Cohen Veterans Bioscience. In March 2022, Odyssey announced the formation of its Military Advisory Board, which supports Odyssey’s outreach efforts to the U.S. Military regarding funding and clinical sites for the treatment of TBIs. The board consists of current and veteran members of the armed forces, including James “Jim” Linder, Francis “Fran” Beaudette, Paul Toolan, and Tim Szymanski. The Sports Advisory Board was formed in March 2021 to support the company’s outreach efforts to enhance public awareness of TBIs and concussions, as well as the need for an FDA-approved therapy. The board consists of Steve “Mooch” Mariucci, Kurt Warner, Brett Favre, Abby Wambach, Mark Rypien, and David Ross. Through its Advisory Boards and Board of Directors, Odyssey is backed by decades of combined experience to further its objectives to meet the needs of patients who are currently without FDA-approved therapies in indications like concussion and TBIs. As demonstrated in its most recent trial, Odyssey’s device and treatment for concussions, Dr. Hack noted, “The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects.” Through this evidentiary analysis, the company is working to commence Phase 2 in the future. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• FingerMotion launched its mobile device protection service on July 15, 2022, banking on the transition to and the proliferation of 5G within the Chinese market
• With the Chinese government targeting over 2 million 5G base stations by the end of the 2022 calendar year, FingerMotion is counting on consumers’ switch from 3G and 4G phones to 5G to grow its new product and market share as a whole
• Martin Shen, FingerMotion’s CEO, is confident that this new direction by the company will not only sustain but also supersede the previous years’ performance, having posted a 12% gross margin growth in 2022, up from 9% in the 2021 financial year
• He has reiterated that the company’s current revenue is “just the tip of the iceberg” and is confident that over the next 6-12 months, FingerMotion will achieve significant revenue growth

FingerMotion’s (NASDAQ: FNGR) latest offering, mobile device protection, launched on July 15, 2022, could not have come at a more opportune time. Mimicking Apple’s AppleCare service but specifically tailored for the Chinese market, FingerMotion sought to capitalize on a largely untapped market, previously limited to broken screen protection (https://ibn.fm/JIZUn). FingerMotion, an evolving technology company with a core competency in mobile payment and recharge platform solutions, has always kept its ear on the ground and has never shied away from exploring new sectors to grow its market share and create value for its shareholders. This outlook has yielded four key offerings: telecommunications products and services, SMS and MMS services, big data insights, and Rich Communication Services (“RCS”). Its latest addition acknowledges the changing consumer behavior and preferences, with many Chinese consumers switching up their older phones for newer ones, specifically those with 5G functionality. “Now with the massive onset of 5G phones, there’s a really large market in China that’s looking to change up their phones for, let’s say, 3G and 4G phones to 5G,” noted Martin Shen, the Chief Executive Officer (“CEO”) of FingerMotion (https://ibn.fm/YDOMc). FingerMotion is looking to bank on this transition and the proliferation of 5G to grow its new product. It believes that in doing so, it will grow its customer numbers and, more importantly, its gross margins, a key objective for the 2023 financial year. In a report published by Open Gov Asia, China is targeting over 2 million 5G base stations by the end of the 2022 calendar year. So far, the country has already launched over 1.4 million base stations serving over 500 million users. The goal for the Chinese government is to have 26 5G base stations for every 10,000 people by the end of 2025, up from five base stations for every 10,000 people in 2020 (https://ibn.fm/E7LpM). With over $900 billion in value added to the Chinese economy by mobile technologies and services, representing 5.6% of the country’s Gross Domestic Product (“GDP”), one would understand why the government is aggressively pushing for 5G infrastructure deployment. Most notably, this move to have 5G accessible to its citizens saw 285 million additional 5G connections in 2021 alone. For a nation where over 1 billion people use mobile internet services, FingerMotion recognizes a tremendous market opportunity for its new product (https://ibn.fm/jXa60). Mr. Shen is confident that this new direction by the company will be integral to sustaining the previous years’ performance and superseding it. Gross margins growth in the 2022 financial year was 12%, with 2021 posting a 9% growth and is hopeful that over the next 6-12 months, FingerMotion will achieve significant revenue growth. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Consensus among autonomous vehicle experts increasingly lean in favor of implementing lidar solutions to promote AV safety
• HD cameras only provide raw image data in 2D; lidar uses laser technology to determine exact distance and location of objects
• Cepton produces state-of-the-art, intelligent, lidar-based applications for AV, ADAS, smart cities, connected spaces, and smart industrial applications
• CPTN engaged with top 10 global automotive OEMs, including GM and Ford

Expert opinions concerning autonomous vehicle (“AV”) safety are leaning in favor of using lidar (light detection and ranging) technologies in addition to HD cameras, a positive development for Cepton (NASDAQ: CPTN), a developer of lidar-based solutions that help enable Advanced Driver Assistance Systems (“ADAS”), AVs, smart cities, connected spaces, and smart industrial applications. The safety of AVs and ADAS hinges on the ability of the vehicle’s system to sense surrounding objects. Both HD cameras and lidar have their benefits and drawbacks; however, lidar is coming out ahead as the technology advances and costs come down. Industry experts like Volkswagen CEO Herbert Diess confirm the growing consensus that lidar is an essential solution (https://ibn.fm/QcNxs). According to Diess, Level 3 driving automation is safer with lidar because it offers redundant perception to 360-degree camera systems. Unlike HD cameras that only provide raw image data in 2D, lidar uses laser technology to determine an object’s exact distance and location. With this ability to detect large and small items at various distances, lidar systems can assign varying importance to objects depending on their proximity and size. Cepton produces state-of-the-art, intelligent, lidar-based applications for AV, ADAS, and other markets, including solutions for smart cities, connected spaces, and smart industrial applications. CPTN’s technology enables seamless high-volume manufacturing in partnership with leading Tier-1s. Cepton is leading the way in scaling up lidar for mass-market deployments. In addition to its significant ADAS lidar series production award with Koito on the General Motors business, Cepton has expanded its lidar use cases across smart infrastructure. “We thought ADAS in the near future would be the biggest market for lidar, and that’s why we focused all of our company efforts – whether it’s in technology invention or commercial development – into the ADAS industry,” said CPTN CEO and lidar pioneer Dr. Jun Pei in a recent interview with the Financial Times (https://ibn.fm/LRxu8). Cepton is also engaged with the other top 10 global automotive OEMs with the aim of making lidar a standard safety feature in all vehicles. For example, Ford Motor Company published an article last year stating that Ford had engaged with CPTN since 2016 for research and development collaboration and small-scale deployments (https://ibn.fm/cPvFO). Working with the team at Ford, Cepton delivered custom lidar solutions that helped enable R&D on advanced ADAS features. In addition, Ford also deployed Cepton’s lidars in some of their smart city projects. Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, with a presence in Germany, Canada, Japan, India, and China to serve a fast-growing customer base. With a dedicated team of researchers and scientists, Cepton aims to make its patented technology mainstream to enable scalable and intelligent 3D perception solutions across multiple major global markets. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Lexaria’s Mexican patent “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Ingredients” joins the ranks of previously issued patents in Australia, India, Japan and the EU
• The patent allows the company to provide value in gaining regulatory approval for its DehydraTECH(TM)-enabled CBD for multiple indications in the health and wellness field
• Additional claims to Mexican patent #390001 include Alzheimer’s disease, Parkinson’s disease, schizophrenia, Human Immunodeficiency Virus (“HIV”) dementia, obesity, hepatic diseases, diabetes, appetite disorders, cancer chemotherapy, benign prostatic hypertrophy, irritable bowel syndrome, biliary diseases, ovarian disorders, marijuana abuse, and alcohol, opioid, nicotine, or cocaine addictions
• The global market of CBD for health and wellness purposes was valued at $4.9 billion in 2021 and is expected to grow to $47.22 billion by 2028

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that the Company has received its 27th worldwide patent, granted in Mexico under registration #390001. The patent from Lexaria’s third patent family, “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents,” has already been issued in Australia, India, and Japan (https://ibn.fm/3hANL). The patent applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a wide variety of ready-to-drink consumer retail beverage products. Lexaria’s latest patent provides value to the company through its continued pursuit of gaining regulatory approval for its patented DehydraTECH(TM)-enabled cannabidiol (“CBD”) for the treatment of hypertension in regulated pharmaceutical applications. This has produced the claims necessary for the Mexico patent to use DehydraTECH-processed non-psychoactive cannabinoids to treat cardiac and cardiometabolic disorders. Additional claims granted to the Mexican patent #390001 include the treatment of neurological diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, and Human Immunodeficiency Virus (“HIV”) dementia. The indications also include obesity, hepatic diseases, diabetes, appetite disorders, cancer chemotherapy, benign prostatic hypertrophy, irritable bowel syndrome, biliary diseases, ovarian disorders, marijuana abuse, and alcohol, opioid, nicotine, or cocaine addictions. Lexaria’s DehydraTECH(TM) technology improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. The technology promotes fast-acting, less expensive, and more effective drug delivery and has been thoroughly evaluated through vivo, in vitro, and human clinical testing. Major benefits of the technology include:

• Increased drug delivery times in which patients feel the effects in a matter of minutes
• Increased bioavailability through the bloodstream
• Increased brain absorption as demonstrated through animal testing with higher drug quantities being delivered across the blood-brain barrier
• Improved drug potency with more of the drug ingested and made available to the body with lower dosing required to achieve maximum results
• Reduction in drug administration costs due to the reduced amount needing to be delivered
• Masking unwanted tastes which reduces the need for unnecessary sweeteners

The global demand for CBD for health and wellness purposes is high, with the worldwide market being valued at $4.9 billion in 2021 and expected to grow at a CAGR of 21.3% from 2022 to 2028, resulting in a value of $47.22 billion by 2028. The rise in demand can be attributed to the increased acceptance and use of CBD for wellness purposes and government approvals (https://ibn.fm/SFw2S). With the approval of its 27th patent, the company is still working on expanding the indications and efficacy of its DehydraTECH(TM) technology – with ~50 pending patents worldwide. The company’s pursuit has allowed it to leverage additional industries, including the need to fill a deficit in the hypertension market. On average, hypertension costs the country $131 billion annually, with more than 670,000 deaths in the United States attributed to hypertension as a primary or contributing factor in 2020. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The Lightning Network offers consumers increased transaction speeds, worldwide access, and lower fees when sending micropayments across its nodes
• LQwD is leveraging the Lightning Network using its own Bitcoin assets to provide solutions for consumers; company plans to expand reach to 24 countries worldwide by the end of the current quarter
• The need for transparency in the financial industry is fueling the growth of the cryptocurrency market, with an anticipated value of US $4.94 billion by 2030

The concept of The Lightning Network was brought to the general public in 2015 when Bitcoin developers Joseph Poon and Thaddeus Dryja published an article about bringing “scalable off-chain payment” to the public. Since then, the layer 2 payment protocol atop the Bitcoin blockchain has grown, providing higher scalability for sending and receiving payments across channels worldwide. With more countries accepting cryptocurrency payments, there is an increased interest coming from community banks and countries seeking to find viable solutions to their banking problems – giving the masses access to payment solutions, faster transaction times, and enhanced security on a global level. Leveraging its own Bitcoin assets, LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption, has expanded its reach, providing Lightning Network nodes across 17 countries and a goal of increasing its presence to 24 countries by the end of the current quarter. LQwD’s first Lightning Network node was released in the US in November 2021 and has since grown to a capacity of over 6 BTC and over 100 channels. In addition to US-West, the company also has nodes in Ireland, India, Germany, Brazil, Hong Kong, Japan, Singapore, Sweden, South Korea, South Africa, Bahrain, France, Canada, Indonesia, Italy, Australia and England. Collectively, these nodes offer users a capacity of over 30 BTC and access to over 300 payment channels. To follow LQwD’s presence on the Lightning Network, visit www.1ML.com. The company also released the first version of its proprietary technology platform-as-a-service (“PaaS”) in November 2021, allowing for easier management of Lightning Network nodes and offering itself as a Liquidity Service Provider (“LSP”) for merchants. Transactions on the Lightning Network offer solutions for users and merchants that exceed the limits in place by other providers. In terms of transactions per second (“TPS”), Bitcoin’s blockchain only offers a capacity of 7 TPS, whereas leading providers like Visa offer 24k TPS. The Lightning Network increases the capabilities for sending and receiving payments exponentially, bypassing leading financial institutions with more than a million TPS. The need for operational efficiency and transparency across payment systems, the rise in demand for remittances in developing countries, increased data security demands, and improved market cap are some of the main factors driving the global cryptocurrency market’s growth, according to Allied Market Research. The market was valued at US $1.49 billion in 2020 and is expected to reach US $4.94 billion by 2030, growing at a CAGR of 12.8% during the forecast period (https://ibn.fm/nrtz0). With countries looking to make payment solutions easier for consumers, the Lightning Network offers a solution that traditional banks cannot – ease of payment, quicker transaction times, and higher levels of security for each transaction. As more community banks pop up in regions to facilitate the financial needs of consumers, the incorporation of the Lightning Network brings new opportunities for facilitating payments where no structure was available before. LQwD is at the forefront of making micropayment transactions quick and affordable for consumers by leveraging its Bitcoin assets to create the channels necessary to facilitate growth across the Lightning Network. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Fossil fuels still account for about 80% of primary energy and 60% of electricity generation globally
• The recent Covid-19 pandemic, and Russia’s invasion of Ukraine, have shown the impact of overreliance on energy supplies, serving as a wake-up call for investors and governments to start making a transition from fossil fuels to more sustainable alternatives
• Correlate is at the forefront of pushing for this transition and is helping enterprises lower their dependence on fossil fuels while boosting their ESG goals
• It recognizes that there are approximately 6.8 million facilities in the U.S. commercial and industrial market that could benefit from its products and services, and is working towards helping them increase their NOI through clean energy solutions
• Correlate is capitalizing on innovation and streamlining its operations to address hurdles in the energy sector to aid an energy transition from fossil fuels to renewable solar energy. This shows how clear its vision is, its knowledge of the current market dynamics, the challenges therein, and how to solve them

Correlate Infrastructure Partners (OTCQB: CIPI), a proprietary clean energy assessment and fulfillment solutions provider, recognizes the current issue with fossil fuel dependence and is helping enterprises shift their focus to more sustainable alternatives while also boosting their environmental, social, and governance (“ESG”) goals. In a recent report released by Wood Mackenzie, a Verisk (NASDAQ: VRSK) business, it was noted that fossil fuels, today, still account for about 80% of primary energy globally. It also noted that despite the significant rise in solar and wind power adoption, fossil fuels still dominate power supplies in most markets, accounting for about 60% of electricity generation worldwide in 2021 (https://ibn.fm/Vz2Rx). The report emphasized the significance of an energy transition to reduce the risk of future shocks. As evidenced by the Covid-19 pandemic, followed by Russia’s invasion of Ukraine, the overreliance on energy supplies, specifically fossil fuels, has dealt a blow to energy security and affordability. This, it argues, serves as a wake-up call for investors and governments to start making a transition and to manage that transition for the benefit of consumers. Recently, Correlate’s focus has been on commercialization as opposed to previous quarters, where it was heavily invested in product development. This has seen it grow its commercial customers, even as it recognizes that there are approximately 6.8 million facilities in the United States commercial and industrial market that could benefit from its energy solution (https://ibn.fm/PVxXK). By helping its commercial customers, Correlate is helping them to increase their net operating income (“NOI”) through clean energy solutions, coupled with the benefits associated with its innovative full-service platform, from solar energy generation to its management. In addition, it hopes to draw the learnings from helping its commercial customers and extend its service to individual consumers who might want to shift to more sustainable and cheaper renewable energy solutions. A report by the Solar Energy Industries Association (“SEIA”) noted that the third quarter of the 2021 calendar year saw a 33% increase in solar capacity compared to the same period the previous year. In addition, solar accounted for 54% of all new electricity-generating capacity added in the country in the first three quarters of 2021 (https://ibn.fm/xeBIS). According to Wood Mackenzie, this rise can be attributed to the significant reduction in costs associated with solar power generation, making it more appealing to enterprises and individuals. It is even projected that the costs will further decline in the long term, which offers an even greater opportunity for Correlate to offer its services to more potential clients and increase its margins as time progresses. So far, Correlate has project opportunities valued at $74 million from recent awards at different stages, including projects that have been awarded agreements in development and contracts that have been executed under installation. With its platform that uses data analysis, development, and financing resources to advise clients on environmental impact reduction and potential savings and profit increases, Correlate is looking to grow its project opportunities significantly over time. Correlate is aiding an energy transition from fossil fuels to renewable solar energy through innovation and streamlining its operations to address hurdles that exist in this sector. More specifically, the company is significantly lowering the barrier of entry into solar energy, which is integral to initiating and sustaining the energy transition from fossil fuels. This is a testament to Correlate’s understanding of its vision and its knowledge of the current market dynamics, the challenges therein, and how to solve them. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• U.S.-based communications technology services provider FingerMotion recently announced a number of milestones in its drive to make its Sapientus big data arm a powerful driver of analytics in China’s billion-strong consumer marketplace
• The company has recently focused development efforts on a ready-to-launch mobile device protection plan similar to AppleCare that the company expects to be competitive in China
• The announcement regarding Sapientus renews expectations that it will evolve beyond its core SMS and mobile top-up services, building on unique partnerships with China’s telecommunication giants and other global corporations
• The Sapientus updates include news that FingerMotion has reached a new agreement with global reinsurance company Pacific Life Re to provide risk-rating capabilities, and that Sapientus’ analytical capabilities have been strengthened

Paying attention to credit score ratings has become a common part of the U.S. consumer’s mindset, particularly during economic downswings when lending interest rates are high and the risks of unemployment are higher (https://ibn.fm/hLNs5). During recent years, mobile technology services provider FingerMotion (NASDAQ: FNGR) has built credit analyzing prowess on its framework of cell phone minutes top-up servicing and SMS texting-related products, recognizing a world of potential in China’s burgeoning consumer market and FingerMotion recently announced upgrades to its credit data technologies to meet the need. China is the most populated country in the world, home to about 1 in every 5 of the earth’s inhabitants, and its growing middle-class workforce is driving a huge economic engine. That engine is largely founded in international trade, amounting to about half its GDP. And its share of GDP in relation to global output rose from 2.5 percent to 17.2 percent during the 35 years between 1980 and 2015. In the process, retail sales reach into the trillions of dollars (https://ibn.fm/rLMRs). But China’s insurance risk and credit risk evaluation infrastructure is still underdeveloped, creating a particular need for big data solutions that can help companies analyze consumer behaviors and create predictive algorithms. U.S.-based FingerMotion’s establishment of partner networks in China that include telecommunications giants China Unicom and China Mobile have made it attractive to other corporate giants as it has built its big data product Sapientus over the past year to serve as a credit risk analysis technology. Global life reinsurance company Pacific Life Re was the first to contract with FingerMotion for consumer risk data to serve Pacific Life’s Re-insurance division in China, and more recently a large New York Stock Exchange-listed insurance company partnered with FingerMotion in its drive to break into the Chinese market. On Aug. 24, FingerMotion announced updates to its Sapientus division, including a new agreement with Pacific Life Re to take that collaboration forward into a new phase, an upgrade of Sapientus’ algorithms with “more elaborative auxiliary data” to strengthen the quality of its analytical results, and the rollout of FingerMotion’s risk-rating API for commercial use. Sapientus has successfully obtained seven patents from the National Copyright Administration of China (“NCAC”) for its proprietary technologies. “Our risk rating API platform is the foundational end product built upon collaborative research conducted with our core partners over the course of the past year,” FingerMotion CEO Martin Shen stated (https://ibn.fm/aSVP1). “We look forward to leveraging this significant achievement and look to realize many more innovation possibilities across the commercialization spectrum.” For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumors
• Glioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cure
• CNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, Berubicin
• Berubicin is an anthracycline (chemotherapy agent) with the apparent ability to cross the blood-brain barrier to attack central nervous system tumors, which grants it a unique status among anthracyclines
• CNS has shown evidence of slowing disease progression among GBM patients and in some instances even shrinking tumor size, and is currently enrolling volunteers in a trial that compares Berubicin against chemotherapeutic agent Lomustine

Bit by bit, medical researchers have been improving treatment options for an aggressive, incurable brain cancer that kills an estimated 10,000-plus people in the United States each year, and more worldwide. Glioblastoma (“GBM”) is generally treated with radiochemotherapy and surgical tumor removal once the cancer is discovered, usually after the sudden onset of headaches and nausea. But eventually, nearly every tumor returns after the initial course of treatment, and the recurrent cancers are increasingly difficult to attack without causing more extreme harm to the patient. Most patients pass away from these tumors 12 to 15 months after first diagnosis (https://ibn.fm/4Qrgy) and only 10 percent reach a five-year survival. Because of glioblastoma’s recognition as an unmet medical need — a currently incurable illness, or one with very ineffective treatments — the field of research to combat it has been competitive. Most recently, investigators at Tel Aviv University (“TAU”) reported success at starving the brain tumors in mice by dealing with the cells surrounding the tumors (https://ibn.fm/nWzO6), with implications for other drug products that might potentially be used against GBM. Biopharmaceutical innovator CNS Pharmaceuticals (NASDAQ: CNSP) is currently conducting a potentially pivotal global Phase 2 clinical trial in humans to test the effectiveness of its anti-GBM drug candidate — Berubicin — after Berubicin testing resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by drug’s original developer over 15 years ago. One patient had a cancer-free response and continues to survive, another experienced a partial response that lasted for 12 weeks and nine patients experienced a stable disease response for over six weeks (https://ibn.fm/wVPVx). The current clinical trial is enrolling patients in up to 54 sites selected in the United States, Italy, France, Spain and Switzerland to compare Berubicin’s response against the standard-of-care chemotherapy agent Lomustine. Twenty-three of those sites are open and operating already. CNS Pharmaceutical recently held its annual stockholder meeting to re-elect officers and conduct other business (https://ibn.fm/sCWx3), following on the company’s announcement of its Q2 performance that showed a general reduction of expenses thanks largely to drug development timing (https://ibn.fm/r2qFY). Among other news in CNS Pharmaceutical’s report, the company indicated its secondary drug portfolio WP1244 — an anthracycline-based substance that is being evaluated for treatment of brain cancers, pancreatic, ovarian, and lymphomas — has produced a new derivative identified as WP1874 with enhanced solubility compared to WP1244. “Going forward, WP1874 will be the primary focus in our development efforts of the WP1244 portfolio,” the company stated. “CNS Pharmaceuticals is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.” CNS anticipates filing for Investigational New Drug (“IND”) recognition for WP1874 in the coming year. Berubicin has already been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (“FDA”). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Exciting times are ahead for solar as US Consumers seem hungry for more renewable energy and government introduces the largest-ever US climate investment
• As energy efficiency becomes priority, this game-changing legislation incentivizes consumers to invest in clean energy upgrades such as solar and wind; demand expected to rise and stay robust over the coming years
• GeoSolar stands ready to respond to this burgeoning market need with its unique system that integrates clean energy technologies such as solar power, geothermal ground-sourced energy and more

Without a doubt, modern consumers seek to lead more sustainable lifestyles and play a meaningful role in the fight for a healthier planet. But as energy prices soar and the cost-of-living balloons, they are also prompted by monetary factors to act toward energy-efficient living. Companies like Colorado-based GeoSolar Technologies (“GST”) appear well placed to ride the new wave of the push for a greener economy as energy transition becomes one of the biggest areas of consideration for consumers, developers, businesses and governments alike. As much as global warming is a high-level global problem requiring a concerted effort of multiple stakeholders worldwide, today’s consumers are ready to rise to the challenge on an individual level, eager to find ways to make their own contributions toward a greener future. A recent survey shows that almost 72% of respondents consider reducing their carbon footprint as nothing less than a personal priority. Over half of them (55%) said they “place importance” on their homes becoming net-zero (https://ibn.fm/WG4W9). The US government is working to make these admirable aspirations possible, offering a myriad of generous incentives for consumers to make a shift to alternative energies. The new landmark legislation known as the Inflation Reduction Act promises to deliver significant savings by allowing hefty tax rebates for green technologies. With nearly $370 billion allocated to green and energy-related projects and incentives, the bill is lauded as “the largest investment ever in combating the existential crisis of climate change.” It is designed to reduce energy costs by directing support to renewable projects, including wind and solar, that can offer a less price volatile source of electricity compared to conventional ones such as gas, coal, and oil. Some developers believe that consumers can get tax credits amounting to as much as 60% of a project’s cost (https://ibn.fm/SB6Ds). The rise of environmental awareness, coupled with swelling energy bills, is expected to spur more household demand for green energy. Solar tax credits have not only been extended until 2032 but have also increased from 26% to 30%. The interest this legislation has generated so far is reportedly off the charts. Installers of solar equipment expect the demand for their services to surge – apparently, enough to keep them busy over the next few years. As the creator of the SmartGreen(R) home system that harnesses energy from the earth and sun to power homes and automobiles, GeoSolar Technologies appears well-placed to capitalize on these changes as a growing number of homeowners take the plunge and join the renewables bandwagon. Renewable technologies can offer unprecedented benefits. For example, once homeowners recoup their solar investment, the electricity this technology generates could practically be free apart from maintenance and service fees for connecting to the power grid. It is estimated that an average house could save from $10,000 to $30,000 over the span of 25 to 30 years, which is the typical shelf life of a solar panel system (https://ibn.fm/u0OZf). With soaring costs of living, managing energy costs are the key driver urging consumers to invest in solutions that put them in control over how energy is produced, stored, and distributed in their homes. They seek green solutions that fulfill their needs both in terms of sustainability and energy bills. With new technologies such as SmartGreen(R) home system, they should be able to do good for the planet and their wallet without compromising on their comfort. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST